Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
WuXi Biologics and HanchorBio partner to develop and manufacture next-gen fusion proteins for cancer and autoimmune treatments using WuXi’s biologics services.
WuXi Biologics and HanchorBio have formed a strategic partnership to develop and manufacture HanchorBio’s next-generation fusion proteins using WuXi’s end-to-end biologics services, including cell line development, process optimization, and GMP manufacturing.
The collaboration supports HanchorBio’s Fc-Based Designer Biologics platform, aimed at treating cancer and autoimmune diseases by targeting both innate and adaptive immunity.
WuXi Biologics will leverage its expertise in complex biologics and proprietary platforms to accelerate clinical development and enable scalable, global production.
As of late 2025, WuXi managed 945 projects, with 60% focused on advanced biologics.
The partnership emphasizes speed, manufacturing robustness, and global compliance to bring innovative therapies to patients.
WuXi Biologics y HanchorBio se asocian para desarrollar y fabricar proteínas de fusión de próxima generación para tratamientos de cáncer y autoinmunes utilizando los servicios biológicos de WuXi.